Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants

Transplantation Proceedings

Volumn 37, Issue 2, 2005, Pages 889-891

  Bunnapradist, S ^a,b   Takemoto, S K ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Health Benchmarks Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; DACLIZUMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; EVALUATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 17844375977     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.12.080     Document Type: Conference Paper

References (5)

1. A.O. Gaber, M.R. First, R.J. Tesi Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation Transplantation 66 1998 29
2. F. Vincenti, R. Kirkman, S. Light Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation Daclizumab Triple Therapy Study Group N Engl J Med 338 1998 161
3. W.S. Cherikh, H.M. Kaufman, M.A. McBride Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation Transplantation 76 2003 1289
4. D.C. Brennan, K. Flavin, J.A. Lowell A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients Transplantation 67 1999 1011
5. A.C. Webster Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials Transplantation 77 2004 166